Comprehensive clinical and molecular portraits of grade 3 ER+ HER-breast cancer

被引：2
|
作者：
Wang, K. [1 ]
Franch-Exposito, S. [2 ]
Li, L. [3 ]
Xiang, T. [4 ]
Wu, J. [3 ]
Ren, G. [4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China
[2] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain
[3] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34P
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] The Future of ER+/HER2-Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2020, 40 (09) : 4829 - 4841
  • [42] Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
    Bahnassy, Shaymaa
    Stires, Hillary
    Jin, Lu
    Tam, Stanley
    Mobin, Dua
    Balachandran, Manasi
    Podar, Mircea
    Mccoy, Matthew D.
    Beckman, Robert A.
    Riggins, Rebecca B.
    ENDOCRINOLOGY, 2023, 164 (12) : 1 - 15
  • [43] Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models
    Mahdi, Amira F.
    Ashfield, Niall
    Conlon, Neil T.
    Crown, John
    Collins, Denis M.
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
    Shuai Li
    Jiayi Wu
    Ou Huang
    Jianrong He
    Li Zhu
    Weiguo Chen
    Yafen Li
    Xiaosong Chen
    Kunwei Shen
    BMC Cancer, 21
  • [45] HER2−/ER+-Brustkrebs: fehlende Taxoleffektivität?HER2−/ER+ breast cancer: lack of effectiveness of taxol?
    N. Bangemann
    Der Onkologe, 2008, 14 (2): : 198 - 200
  • [46] Estimating the cost of adjuvant chemotherapy in ER+/HER2-early breast cancer and distant recurrence of breast cancer in the UK
    Berdunov, V.
    Millen, S.
    Paramore, A.
    Reynia, S.
    Fryer, N.
    Griffin, J.
    Georges, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S46 - S46
  • [47] Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+breast cancer
    Turnbull, A. K.
    Webber, V.
    McStay, D.
    Arthur, L.
    Martinez-Perez, C.
    Fernando, A.
    Renshaw, L.
    Keys, J.
    Clarke, R.
    Sims, A. H.
    Dixon, J. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Role of endocrine therapy in ER+/HER2(+) breast cancers
    Webber, Victoria L.
    Dixon, J. Michael
    BREAST CANCER MANAGEMENT, 2014, 3 (01) : 103 - 111
  • [49] Complex rearrangements fuel ER+ and HER2+ breast tumours
    Houlahan, Kathleen E.
    Mangiante, Lise
    Sotomayor-Vivas, Cristina
    Adimoelja, Alvina
    Park, Seongyeol
    Khan, Aziz
    Pribus, Sophia J.
    Ma, Zhicheng
    Caswell-Jin, Jennifer L.
    Curtis, Christina
    NATURE, 2025, : 510 - 518
  • [50] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    CANCER RESEARCH, 2019, 79 (04)
12345